Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales
This article was originally published in The Pink Sheet Daily
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call
You may also be interested in...
Organon is preparing its response to congressional investigators looking into the handling of pediatric research for antidepressants, the company said during a July 19 conference call
A conflict caused the Energy & Commerce/Oversight Subcommittee to postpone a July 20 hearing on clinical trial publication and disclosure issues. Results from a new study evaluating suicidal behavior in patients taking SSRIs versus tricyclic antidepressants could be a topic of discussion during the rescheduled hearing.
The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.